Revealing structural basis for development of a novel drug against multidrug-resistant HIV

2016 Fiscal Year Final Research Report

• Project/Area Number: 24790049
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Physical pharmacy
• Research Institution: Iwaki Meisei University
• Principal Investigator: suzuki kaoru いわき明星大学, 薬学部, 客員研究員 (90382788)
• Project Period (FY): 2012-04-01 – 2017-03-31
• Keywords: HIV感染 / 抗HIV薬 / タンパク質 / 糖鎖 / レクチン / Ｘ線結晶構造解析 / 感染症 / 薬学

Outline of Final Research Achievements

HIV/AIDS is a major health concern, it is a global pandemic which remains relatively uncontrolled infectious disease. We independently succeeded in discovering a new lectin, actinohivin (hereafter designate AH), from actinomycete. AH is an excellent candidate for development as an antiretrovial drug to treat or prevent HIV infection.
In order to obtain structural insights into the anti-HIV activity of AH, we crystallized AH and in complex with the target α(1-2)mannobiose (Man2) and α(1-2)(1-2）mannotriose (Man3) moiety of the high-mannose-type glycan (HMTG) attached to HIV-1 gp120. Its crystal structure was successfully solved, revealing that AH is composed of three repeated modules that are closely associated with each other.The present study confirmed that the three mannobiose-binding pockets of AH are almost the same or equivalent and that their tertiary structures are rather rigid.

Free Research Field

構造生物学